There are 2867 resources available
1528TiP - A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS)
Presenter: Matthew Ingham
Session: Poster session 11
1115P - Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan
Presenter: Masanobu Okahisa
Session: Poster session 15
843P - Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
Presenter: Takami Sato
Session: Poster session 03
1648P - Deep learning identifies oncogenic genetic alterations in BRAF and NTRK in H&E whole slide images from thyroid carcinomas
Presenter: Michelle Williams
Session: Poster session 11
1116P - United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review
Presenter: Maximilian Julve
Session: Poster session 15
844P - Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Presenter: James Larkin
Session: Poster session 03
1649P - A proof-of-concept study for detecting ctDNA in rare thyroid cancers
Presenter: Danica Vodopivec Kuri
Session: Poster session 11
1117P - Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy
Presenter: Nicolas Girard
Session: Poster session 15
845P - Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study
Presenter: John Kirkwood
Session: Poster session 03